Patients with locally advanced or inflammatory HER-2–positive breast cancer who underwent neoadjuvant chemotherapy plus trastuzumab followed by adjuvant trastuzumab demonstrated durable EFS, according to updated phase 3 study results.
The analysis included 235 patients with HER-2–positive breast cancer. Of these patients, 118 received chemotherapy alone, and 117 received chemotherapy plus trastuzumab (Herceptin, Genentech) for 1 year before and after surgery. Ninety-nine patients with HER-2–negative disease who were included in a parallel cohort received neoadjuvant chemotherapy alone.
Full Story »
Personalize your page!
Register for Healio to get content tailored to your specialty and areas of interest.
It’s FREE and only takes one minute.